Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This article reviewed the effectiveness and safety of CAR T-cell therapy in patients with non-Hodgkin’s lymphoma.

Some background

The standard treatment for non-Hodgkin’s lymphoma (NHL) is chemotherapy plus immunotherapy. Patients with high-risk disease tend to become refractory (do not respond to treatment). For these patients, treatment options are limited.

CAR T-cell therapy is a new type of treatment for patients with a poor prognosis. This treatment is usually given after a chemotherapy regimen. In this treatment, T-cells (immune cells) are removed from the blood. The T-cells are genetically modified to make a special protein called CAR. This protein helps the T-cells attack cancer cells. These CAR T-cells are then reintroduced into the patient.

Methods & findings

This review analyzed the use of CAR T-cell therapy in NHL.

For aggressive NHL, one study involved 101 patients. These patients had refractory diffuse large B-cell lymphoma (DLBCL). 83% of patients responded to treatment. 54% of patients achieved a complete response (disappearance of all signs of cancer). Progression-free survival (patients alive without return of disease) was 41% at 18 months. Overall survival (patients still alive) was 52% at 18 months.

93% of patients in this trial reported cytokine release syndrome (symptoms associated with rapid release of immune molecules into the blood). 35% of patients reported infections. 64% of patients reported neurotoxicity (side effects in the nervous system). Of these, 13% (cytokine release syndrome), 31% (infections), and 28% (neurotoxicity) were severe to life threatening.

For indolent (painless) NHL, one study involved 32 patients. Of these, 18.9% had follicular lymphoma. 80% of these patients responded to treatment. 40% of patients achieved a complete response. Another study involved 14 patients with refractory follicular lymphoma. 79% of patients responded after 3 months of treatment. 50% of patients achieved a complete response. After a follow-up of 28.6 months, 70% of patients were disease-free.

The bottom line

This article reviewed the effectiveness and safety of CAR T-cell therapy in patients with non-Hodgkin’s lymphoma. These included diffuse large B-cell lymphoma and follicular lymphoma.

Published By :

Best practice & research. Clinical haematology

Date :

Jun 01, 2018

Original Title :

CAR T cell therapy for B-cell lymphomas.

click here to get personalized updates